Navigating the Complexities of NMOSD: A Disease That Demands Vigilance and Evolving Strategies
Neuromyelitis optica spectrum disorder (NMOSD) is a neurological tightrope walk for clinicians. Its potential for devastating relapses, chameleon-like symptoms mimicking other conditions like MOGAD and MS, and the urgent need for pinpoint diagnosis make it a true diagnostic and therapeutic challenge. But here's where it gets even more intricate: the landscape of NMOSD is constantly shifting. Evolving diagnostic criteria, a deeper understanding of seropositive and seronegative variations, and emerging treatment options demand constant adaptation from neurologists.
Recent updates, including the 2025 revisions to NMOSD criteria, shed light on crucial distinctions in disease biology, the reliability of tests, and how patients respond to treatment. This underscores the absolute necessity of clinical vigilance and high-quality antibody testing as cornerstones of effective care.
In a recent discussion, Dr. Elena Grebenciucova, a neuroimmunology expert and assistant professor of neurology at Northwestern University, delves into the practical and emerging complexities of managing NMOSD. She provides a comprehensive roadmap, highlighting diagnostic pitfalls, the clinical implications of seronegative presentations, the evolving landscape of long-term immunotherapy, and crucial considerations for special populations like pregnant patients and those battling multiple autoimmune diseases. Her insights offer a grounded, clinically relevant guide for neurologists navigating the daily challenges of NMOSD.
NeurologyLive®: For young clinicians entering the field of neuroimmunology, what are the most critical aspects of NMOSD to master for effective treatment?
Dr. Elena Grebenciucova: The foundation lies in recognizing the clinical syndrome. Optic neuritis, especially when severe or affecting both eyes, should immediately trigger testing for aquaporin-4 and MOG antibodies. It's crucial to remember that optic neuritis can present subtly, and even mild cases warrant antibody testing. A common pitfall is the choice of specimen. Serum, not cerebrospinal fluid, is the gold standard for both aquaporin-4 and MOG antibody testing. This misconception often leads to missed diagnoses. High-quality testing is paramount, utilizing live cell-based assays for optimal sensitivity and specificity.
Two main types of cell-based assays exist: live and fixed. While the fixed assay has slightly lower sensitivity for aquaporin-4, its specificity remains excellent, meaning a positive result is highly reliable. ELISA testing is outdated and unreliable; patients previously tested with ELISA require immediate retesting with a live cell-based assay. Timing is critical – ideally, testing should occur during the acute phase. However, results can be falsely negative if the patient has already received immunotherapy like plasma exchange, high-dose steroids, or rituximab. In such cases, retesting after 3-6 months is essential. Even if initial results are negative but clinical suspicion remains high, vigilance is key. Retesting with any future relapse, preferably before initiating immunotherapy, is crucial. These considerations are fundamental when diagnosing NMOSD and related disorders.
And this is the part most people miss... The 2025 NMOSD criteria revisions highlight a significant shift: the former "seronegative NMOSD" is now termed "seronegative NMOSD clinical syndromes." This change reflects a growing understanding that aquaporin-4 positive NMOSD has a distinct pathobiology – an antibody-driven, complement-mediated disease with characteristic biopsy patterns and CSF biomarkers. In contrast, double-seronegative cases (both MOG and aquaporin-4 negative) lack a uniform biological signature. Biopsies and postmortem studies reveal diverse pathologies, varying CSF profiles, and significantly different responses to standard NMOSD medications.
Studies on therapies like anti-IL-6 agents further emphasize this distinction. The seronegative group doesn’t respond uniformly like aquaporin-4 positive patients. This heterogeneity, highlighted by Dr. Wingerchuk at ECTRIMS, underscores that double-seronegative presentations represent a spectrum of syndromes rather than a single disease entity. This has profound implications for treatment selection and patient counseling. Clinicians must embrace diagnostic flexibility, recognizing that seronegative presentations may stem from diverse underlying processes, and treatment responsiveness will vary accordingly.
But here's where it gets controversial... Long-term immunotherapy and de-escalation strategies for NMOSD remain a subject of ongoing debate. For aquaporin-4 positive NMOSD, the majority of patients experience relapsing disease and require long-term treatment. Fortunately, we have several FDA-approved options, including complement inhibitors, anti-CD19 therapy, and anti-IL-6 therapy. However, de-escalation is challenging in aquaporin-4 disease. Unlike MS, where older patients may experience fewer relapses, NMOSD relapses can occur even in patients in their seventies and can be severe. Therefore, in my practice, we generally avoid completely discontinuing therapy.
In some cases, we may switch therapies, particularly in aging patients prone to recurrent infections. Here, we might transition from a broadly immunosuppressive agent to one with a more favorable infection risk profile. However, completely stopping therapy is rarely recommended in aquaporin-4 positive disease.
A Call for Further Exploration: Managing NMOSD in special populations like pregnant patients, pediatric patients, and those with coexisting autoimmune conditions presents unique challenges. More research is desperately needed. Unlike MS, where pregnancy often has a protective effect, NMOSD carries a risk of relapse during pregnancy. While continuing treatment with medications deemed reasonably safe during pregnancy may be considered on a case-by-case basis, we urgently need clearer guidelines to safeguard pregnant patients with NMOSD during this vulnerable period.
Coexisting autoimmune diseases, such as lupus, further complicate the picture. AQP4-positive NMOSD frequently overlaps with lupus, and we need more data on how NMOSD therapies interact with modern lupus medications. As treatment options expand for both diseases, safety and efficacy considerations become increasingly complex. Continued research is vital to inform optimal management strategies for these special patient groups.
Food for Thought: As our understanding of NMOSD evolves, so too must our diagnostic and therapeutic approaches. The distinction between seropositive and seronegative NMOSD is not merely semantic; it has profound implications for treatment and patient outcomes. Should we be moving towards a more personalized medicine approach, tailoring treatment based on specific antibody profiles and disease biology? How can we best support pregnant women with NMOSD, balancing the risks and benefits of treatment during this critical period? These are the questions that continue to fuel research and drive innovation in the field of neuroimmunology. What are your thoughts? Share your perspectives in the comments below.
